Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
AIM We aim ed to assess the effects of rosuvastatin treatment on lipid levels , a biomarker of oxidative stress , albuminuria , and kidney function in patients with diabetic nephropathy . METHODS We conducted a prospect i ve , open-label , parallel group , controlled study of 104 patients with diabetic nephropathy , low-density lipoprotein cholesterol ( LDL-C ) levels of > 120 mg/dL , and well-controlled blood pressure who were undergoing treatment with renin angiotensin system inhibitors .  Patients were r and omly assigned to two groups : the rosuvastatin group ( n = 52 ; 2.5 mg/day rosuvastatin , increased to 10 mg/day ) and the control group ( n = 52 ; no rosuvastatin administered ) . We determined the efficacy of rosuvastatin by monitoring serum lipid profiles , high sensitivity C-reactive protein ( hs-CRP ) , malondialdehyde-modified LDL ( MDA-LDL ) , and cystatin C levels . In addition , urinary albumin , 8-hydroxydeoxyguanosine ( 8-OHdG ) and liver-type fatty acid-binding protein ( L-FABP ) levels were measured before and 6 months after rosuvastatin was added to the treatment . RESULTS Rosuvastatin effectively reduced total cholesterol , LDL-C , triglycerides , non-high-density lipoprotein cholesterol ( non-HDL-C ) levels , and the LDL-C/ HDL-C ratio in the rosuvastatin group . These parameters remained unchanged in patients who were not treated with rosuvastatin . Although there was no significant change in the estimated glomerular filtration rate level , serum cystatin C levels and urinary albumin excretion rates were significantly decreased in the rosuvastatin group . In addition , rosuvastatin significantly reduced hs-CRP and MDA-LDL levels . Moreover , urinary 8-OHdG and L-FABP levels at baseline ( 13.5±5.1 and 41.7±26.1 ng/mgCr , respectively ) decreased significantly at 6 months ( 11.5±4.0 and 26.9±13.4 ng/mgCr , respectively ) , and there was a significant correlation ( r = 0.48 , p < 0.01 ) . Multivariate analysis revealed that albuminuria was significantly correlated with only rosuvastatin use ( p = 0.0006 , R(2)= 0.53 ) . CONCLUSION Rosuvastatin administration reduced albuminuria , oxidative stress , and serum cystatin C levels , independent of blood pressure and lipid levels
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .